Dr Reddy's Labs shares in focus after Q2 profit falls 15% YoY. What should investors do?
Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While ...
ndtvprofit34m
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
ndtvprofit38m
Dr. Reddy’s Q2 Results Review - Performance Inline With Expectations; Upgrade To 'Hold': Systematix
The brokerage expects the new business avenues to take a few years before they start contributing profitably to the ...
Dr Reddy's Q2 performance sees revenue boost, but challenges persist
Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong ...
Dr Reddys Stocks: Dr. Reddy's Laboratories ended the previous trading day at Rs 1272.20.
Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...